185 related articles for article (PubMed ID: 17376040)
21. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia.
Hyogo H; Tazuma S; Arihiro K; Iwamoto K; Nabeshima Y; Inoue M; Ishitobi T; Nonaka M; Chayama K
Metabolism; 2008 Dec; 57(12):1711-8. PubMed ID: 19013295
[TBL] [Abstract][Full Text] [Related]
22. How different is the dietary pattern in non-alcoholic steatohepatitis patients?
Cortez-Pinto H; Jesus L; Barros H; Lopes C; Moura MC; Camilo ME
Clin Nutr; 2006 Oct; 25(5):816-23. PubMed ID: 16677739
[TBL] [Abstract][Full Text] [Related]
23. Association of liver disease with postprandial large intestinal triglyceride-rich lipoprotein accumulation and pro/antioxidant imbalance in normolipidemic non-alcoholic steatohepatitis.
Musso G; Gambino R; De Michieli F; Biroli G; Fagà E; Pagano G; Cassader M
Ann Med; 2008; 40(5):383-94. PubMed ID: 18484349
[TBL] [Abstract][Full Text] [Related]
24. A new model for nonalcoholic steatohepatitis in the rat utilizing total enteral nutrition to overfeed a high-polyunsaturated fat diet.
Baumgardner JN; Shankar K; Hennings L; Badger TM; Ronis MJ
Am J Physiol Gastrointest Liver Physiol; 2008 Jan; 294(1):G27-38. PubMed ID: 17947452
[TBL] [Abstract][Full Text] [Related]
25. Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis.
Satapathy SK; Sakhuja P; Malhotra V; Sharma BC; Sarin SK
J Gastroenterol Hepatol; 2007 May; 22(5):634-8. PubMed ID: 17444848
[TBL] [Abstract][Full Text] [Related]
26. Risk factors associated with nonalcoholic fatty liver disease and its relationship with the hepatic histological changes.
Rodríguez-Hernández H; Gonzalez JL; Márquez-Ramirez MD; Flores-Hernandez M; Rodríguez-Morán M; Guerrero-Romero F
Eur J Gastroenterol Hepatol; 2008 May; 20(5):399-403. PubMed ID: 18403941
[TBL] [Abstract][Full Text] [Related]
27. A cross-sectional study assessing dietary intake and physical activity in Canadian patients with nonalcoholic fatty liver disease vs healthy controls.
Da Silva HE; Arendt BM; Noureldin SA; Therapondos G; Guindi M; Allard JP
J Acad Nutr Diet; 2014 Aug; 114(8):1181-94. PubMed ID: 24631112
[TBL] [Abstract][Full Text] [Related]
28. Serotonin mediates oxidative stress and mitochondrial toxicity in a murine model of nonalcoholic steatohepatitis.
Nocito A; Dahm F; Jochum W; Jang JH; Georgiev P; Bader M; Renner EL; Clavien PA
Gastroenterology; 2007 Aug; 133(2):608-18. PubMed ID: 17681180
[TBL] [Abstract][Full Text] [Related]
29. Effects of vitamin E treatment on peroxisome proliferator-activated receptor-alpha expression and insulin resistance in patients with non-alcoholic steatohepatitis: results of a pilot study.
Yakaryilmaz F; Guliter S; Savas B; Erdem O; Ersoy R; Erden E; Akyol G; Bozkaya H; Ozenirler S
Intern Med J; 2007 Apr; 37(4):229-35. PubMed ID: 17388862
[TBL] [Abstract][Full Text] [Related]
30. Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis.
Idilman R; Mizrak D; Corapcioglu D; Bektas M; Doganay B; Sayki M; Coban S; Erden E; Soykan I; Emral R; Uysal AR; Ozden A
Aliment Pharmacol Ther; 2008 Jul; 28(2):200-8. PubMed ID: 18445142
[TBL] [Abstract][Full Text] [Related]
31. Clerodendron glandulosum.Coleb extract ameliorates high fat diet/fatty acid induced lipotoxicity in experimental models of non-alcoholic steatohepatitis.
Jadeja RN; Thounaojam MC; Dandekar DS; Devkar RV; Ramachandran AV
Food Chem Toxicol; 2010 Dec; 48(12):3424-31. PubMed ID: 20849909
[TBL] [Abstract][Full Text] [Related]
32. Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients.
Videla LA; Rodrigo R; Orellana M; Fernandez V; Tapia G; Quiñones L; Varela N; Contreras J; Lazarte R; Csendes A; Rojas J; Maluenda F; Burdiles P; Diaz JC; Smok G; Thielemann L; Poniachik J
Clin Sci (Lond); 2004 Mar; 106(3):261-8. PubMed ID: 14556645
[TBL] [Abstract][Full Text] [Related]
33. [Non-alcoholic fatty liver disease--new view].
Raszeja-Wyszomirska J; Lawniczak M; Marlicz W; Miezyńska-Kurtycz J; Milkiewicz P
Pol Merkur Lekarski; 2008 Jun; 24(144):568-71. PubMed ID: 18702346
[TBL] [Abstract][Full Text] [Related]
34. Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
Younossi ZM
Aliment Pharmacol Ther; 2008 Jul; 28(1):2-12. PubMed ID: 18410557
[TBL] [Abstract][Full Text] [Related]
35. Metabolic disturbances in non-alcoholic fatty liver disease.
Byrne CD; Olufadi R; Bruce KD; Cagampang FR; Ahmed MH
Clin Sci (Lond); 2009 Apr; 116(7):539-64. PubMed ID: 19243311
[TBL] [Abstract][Full Text] [Related]
36. Glucose abnormalities in non-alcoholic fatty liver disease and chronic hepatitis C virus infection: the role of iron overload.
Lecube A; Hernández C; Simó R
Diabetes Metab Res Rev; 2009 Jul; 25(5):403-10. PubMed ID: 19444865
[TBL] [Abstract][Full Text] [Related]
37. The expression of SIRT1 in nonalcoholic fatty liver disease induced by high-fat diet in rats.
Deng XQ; Chen LL; Li NX
Liver Int; 2007 Jun; 27(5):708-15. PubMed ID: 17498258
[TBL] [Abstract][Full Text] [Related]
38. High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease.
Kantartzis K; Thamer C; Peter A; Machann J; Schick F; Schraml C; Königsrainer A; Königsrainer I; Kröber S; Niess A; Fritsche A; Häring HU; Stefan N
Gut; 2009 Sep; 58(9):1281-8. PubMed ID: 19074179
[TBL] [Abstract][Full Text] [Related]
39. [Role of oxidative stress in non-alcoholic steatohepatitis].
Mitsuyoshi H; Itoh Y; Okanoue T
Nihon Rinsho; 2006 Jun; 64(6):1077-82. PubMed ID: 16768112
[TBL] [Abstract][Full Text] [Related]
40. Differential expression of miRNAs in the visceral adipose tissue of patients with non-alcoholic fatty liver disease.
Estep M; Armistead D; Hossain N; Elarainy H; Goodman Z; Baranova A; Chandhoke V; Younossi ZM
Aliment Pharmacol Ther; 2010 Aug; 32(3):487-97. PubMed ID: 20497147
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
